Novartis Ag (NVS) EPS (Basic) Growth (3y) (2012 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Basic) Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
77.05% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
320.46% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-14.12% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-21.17% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.65% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2025 |
-99.87% |
| Dec 31, 2024 |
48.85% |
| Jun 30, 2024 |
78,987.07% |
| Dec 31, 2023 |
-52.69% |
| Sep 30, 2023 |
50,952.67% |
| Jun 30, 2023 |
-79.27% |
| Mar 31, 2023 |
87,885.71% |
| Mar 31, 2022 |
101.43% |
| Dec 31, 2021 |
362.23% |
| Sep 30, 2021 |
66.40% |
| Jun 30, 2021 |
-99.39% |
| Mar 31, 2021 |
111.09% |
| Dec 31, 2020 |
60.17% |
| Sep 30, 2020 |
-99.86% |
| Jun 30, 2020 |
-99.87% |
| Mar 31, 2020 |
-99.93% |
| Mar 31, 2019 |
-25.99% |
| Dec 31, 2018 |
-150.12% |
| Sep 30, 2018 |
-25.99% |
| Jun 30, 2018 |
7,882.79% |
| Mar 31, 2018 |
-95.20% |
| Dec 31, 2017 |
1,224.06% |
| Sep 30, 2017 |
17,968.73% |
| Jun 30, 2017 |
34,643.27% |
| Mar 31, 2017 |
11,189.95% |
| Sep 30, 2016 |
18,139.13% |
| Jun 30, 2016 |
20,886.83% |
| Sep 30, 2015 |
5,671.22% |
| Jun 30, 2015 |
-27.68% |
| Mar 31, 2015 |
10,764.22% |
| Dec 31, 2014 |
-42.20% |
| Sep 30, 2014 |
-36.69% |
| Jun 30, 2014 |
-28.71% |
| Mar 31, 2014 |
-4.13% |
| Sep 30, 2013 |
-42.08% |
| Jun 30, 2013 |
-27.76% |
| Sep 30, 2012 |
695.61% |
| Jun 30, 2012 |
6,874.68% |
| Mar 31, 2012 |
-92.50% |
